{"title":"Discordant patterns of anterior abdominal wall radiotracer accumulation in yttrium-90 selective internal radiation therapy: implications for pretherapeutic planning and posttreatment monitoring.","authors":"Huanyu Gong, Yong Cheng, Jingjie Shang, Qijun Cai, Yingxin Li, Kangshou Liu, Yulong Liu, Jian Gong, Hao Xu","doi":"10.1097/MNM.0000000000002035","DOIUrl":"10.1097/MNM.0000000000002035","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the differential patterns of anterior abdominal wall (AAW) radiotracer accumulation using pretherapeutic technetium-99m macroaggregated albumin ( 99m Tc-MAA) single photon emission computed tomography/computed tomography (SPECT/CT) and posttherapeutic yttrium-90 ( 90 Y) positron emission tomography/CT (PET/CT) imaging in 90 Y resin microspheres selective internal radiation therapy (SIRT).</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on 204 patients with unresectable liver malignancies who underwent SIRT between August 2022 and November 2024. Pretherapeutic evaluation included diagnostic angiography and 99m Tc-MAA imaging. Posttherapeutic 90 Y-PET/CT was performed within 24 h of treatment to verify microspheres distribution. Patients with AAW accumulation on 99m Tc-MAA images or 90 Y-microspheres PET/CT images were analyzed, and follow-up results for at least 3 months served as reference standards.</p><p><strong>Results: </strong>Among 204 patients, 21 (10.3%) showed AAW accumulation on 99m Tc-MAA images or 90 Y-microspheres PET/CT images. Concordant findings between 99m Tc-MAA images and 90 Y-PET/CT images were observed in 11(11/21, 52.4%) cases, while five cases (5/21, 23.8%) showed accumulation only on 90 Y-PET/CT images, and the other five cases (5/21, 23.8%) showed accumulation only on 99m Tc-MAA images. The hepatic falciform artery (HFA) was found in two patients. Mild abdominal pain was observed in four patients, and only one patient experienced abdominal dermatitis, which resolved spontaneously. The remaining patients did not experience any relevant side effects during the follow-up period.</p><p><strong>Conclusion: </strong>AAW-related complications were infrequent and mild, suggesting that a patent HFA may not be considered a contraindication for SIRT; however, discordance between 99m Tc-MAA and 90 Y-PET/CT highlights the need for vigilant posttreatment monitoring, even in cases without pretherapeutic AAW accumulation.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1029-1036"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144784945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Merve Nur Acar Tayyar, Ercan Uyanik, Mehmet Mülazimoğlu, Müge Öner Tamam, Savaş Karyağar, Meryem Eslem Biçen Altin, Fatma Zehra Yildiz Kabaca, Merve Cinoğlu Karaca
{"title":"Graves' disease: is hyperthyroidism still present 6 months after radioactive iodine treatment really a failure?","authors":"Merve Nur Acar Tayyar, Ercan Uyanik, Mehmet Mülazimoğlu, Müge Öner Tamam, Savaş Karyağar, Meryem Eslem Biçen Altin, Fatma Zehra Yildiz Kabaca, Merve Cinoğlu Karaca","doi":"10.1097/MNM.0000000000002033","DOIUrl":"10.1097/MNM.0000000000002033","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to evaluate the accuracy of the 6-month evaluation to accept treatment failure after a single dose of radioactive iodine (RAI) for Graves' disease and to decide whether to repeat the dose.</p><p><strong>Methods: </strong>This study retrospectively analyzed 104 patients who received a single dose of RAI between 2003 and 2022, had regular follow-up for at least 2 years, and did not have extrathyroidal symptoms. The study group was divided into two groups: patients who developed hypothyroidism within the first 6 months and patients who developed hypothyroidism after 6 months, and statistically analyzed.</p><p><strong>Results: </strong>The mean administered dose of RAI was 10.6 ± 4.4 mCi, and the average duration of hypothyroidism was 5.5 ± 5.4 months. In patients with late-onset hypothyroidism (>6 months), the 2-h iodine uptake values were significantly higher, and post-RAI thyroid-stimulating hormone levels were significantly lower. While 58.5% of patients with early-onset hypothyroidism (<6 months) required antithyroid drug (ATD) therapy after RAI, all patients who developed hypothyroidism after 6 months received supportive ATD treatment. The 24-h iodine uptake values were significantly higher in the hypothyroid group compared with the euthyroid group. During follow-up, 26.9% of patients were hypothyroid at 0-3 months, 62.5% at 3-6 months, and 77.9% at 12 months. While 20.2% of patients remained hyperthyroid at 6 months, this rate declined to 3.8% at 12 months.</p><p><strong>Conclusion: </strong>This study suggests that the 6 th month following RAI treatment in patients with Graves' disease may not be sufficient to assess treatment response, as hypothyroidism tends to develop cumulatively over time. Iodine uptake values at 2 and 24 h may serve as useful indicators for predicting the development of early or late hypothyroidism, while also helping to guide the maintenance of a euthyroid state.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1037-1042"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jairo Cajamarca-Baron, Juan Pablo Castañeda-Gonzalez, Gabriel E Acelas-Gonzalez, Daniel Felipe Galindo-Cortés, Edward Diaz, Catalina Sanmiguel-Reyes, Diana Guavita-Navarro, Adriana Rojas-Villarraga
{"title":"Utilization of PET in diagnosing adult-onset Still's disease: a systematic review.","authors":"Jairo Cajamarca-Baron, Juan Pablo Castañeda-Gonzalez, Gabriel E Acelas-Gonzalez, Daniel Felipe Galindo-Cortés, Edward Diaz, Catalina Sanmiguel-Reyes, Diana Guavita-Navarro, Adriana Rojas-Villarraga","doi":"10.1097/MNM.0000000000002039","DOIUrl":"10.1097/MNM.0000000000002039","url":null,"abstract":"<p><p>Adult-onset Still's disease (AOSD) is a rare systemic inflammatory disorder that frequently presents as fever of unknown origin (FUO), posing a diagnostic challenge. This study aimed to systematically review the diagnostic utility of 18 F-labeled fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography (CT) in AOSD. A systematic review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered in PROSPERO (CRD42023443831). Databases searched included PubMed, EMBASE, and Ovid up to December 2022. We included case reports, case series, cross-sectional, case-control, cohort studies, and clinical trials reporting PET/CT findings in adult patients diagnosed with AOSD. Data extraction included demographics, PET/CT findings, tracers used, standardized uptake values (SUVs), and diagnostic criteria applied. Data were analyzed following the SWiM framework because of heterogeneity. From 155 records, 54 studies (545 patients) were included. The majority were case reports or series ( n = 40), with 14 observational studies or trials. 18 F-FDG was used in 85% of cases, predominantly for diagnostic purposes (77.7%). The most commonly used diagnostic criteria were Yamaguchi (63%). The highest maximum SUV (SUV max ) values were observed in the bone marrow (4.0 ± 1.4), spleen (4.0 ± 1.9), and liver (4.2 ± 2.1). PET/CT findings frequently revealed diffuse hypermetabolism in these organs, aiding in distinguishing AOSD from infectious or malignant etiologies. 18 F-FDG PET/CT appears to be a useful adjunct in the diagnostic workup of AOSD, especially in cases presenting as FUO. Typical uptake patterns in bone marrow, spleen, liver, and lymph nodes may support the diagnosis, though biopsy remains essential to exclude neoplastic mimics.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"1020-1028"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144963868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maurits Wondergem, Friso M van der Zant, Sergiy V Lazarenko, Jeroen Doodeman, Ton A Roeleveld, Remco J J Knol
{"title":"18F-DCFPyL and 18F-PSMA-JK7 for staging of primary prostate cancer: an interpatient comparison in 500 patients.","authors":"Maurits Wondergem, Friso M van der Zant, Sergiy V Lazarenko, Jeroen Doodeman, Ton A Roeleveld, Remco J J Knol","doi":"10.1097/MNM.0000000000002027","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002027","url":null,"abstract":"<p><strong>Rationale: </strong>Staging primary prostate cancer with prostate specific membrane antigen (PSMA) PET/computed tomography is incorporated in recent guidelines, given its pivotal role in guiding therapy selection and prognostication. Little is known about differences in diagnostic performance between different PSMA tracers. In this study the performance of 18F-DCFPyL (PyL) is compared with 18F-PSMA-JK7 (JK7) in primary staging.</p><p><strong>Methods: </strong>Interpatient comparison of 250 patients scanned with PyL and 250 with JK7. Detection of primary lesions and metastases in locoregional lymph nodes, distant lymph nodes, bone, and other distant metastases as well as clinical outcomes in an operated subcohort were compared. Differences were reported as odds ratios (ORs) and were calculated by means of an univariable and multivariable logistic regression.</p><p><strong>Results: </strong>No significant differences in detection of metastases between PyL and JK7 were found; locoregional lymph nodes (OR: 0.81, P = 0.34), distant lymph nodes (OR: 1.15, P = 0.60), bone (OR: 0.91, P = 0.72) and other distant metastases (OR: 0.95, P = 0.91). In a subcohort of 68 operated patients the true-negative rate was 86 and 90% and the false-negative rate was 14 and 10% for PyL and JK7 (P = 0.52), respectively.</p><p><strong>Conclusion: </strong>No clinically relevant differences are found between PyL and JK7 for staging of primary prostate cancer. Both in terms of detection rates of primary tumor and metastases as well as in terms of PET true-negative and false-negative rates in the subcohort treated with surgery. This data indicates that the diagnostic value of JK7 is comparable to PyL.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"46 11","pages":"1061-1068"},"PeriodicalIF":1.3,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rashid Rasheed, A M Mutawa, Shah P Numani, Amir Masud, Muhammad Shahid, Abubakr Muhammad Maher, Sheema Mansoor, Layla Ghadanfer, Sharjeel Usmani
{"title":"Diagnostic practice points of multimodality imaging in cardiac amyloidosis: a summary of diagnostic perspective.","authors":"Rashid Rasheed, A M Mutawa, Shah P Numani, Amir Masud, Muhammad Shahid, Abubakr Muhammad Maher, Sheema Mansoor, Layla Ghadanfer, Sharjeel Usmani","doi":"10.1097/MNM.0000000000002057","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002057","url":null,"abstract":"<p><p>Cardiac amyloidosis (CA) is an emerging iceberg among the cardiomyopathies with significant morbidity and mortality. The overlapping signs and symptoms with other cardiac pathologies warrant prompt identification of the clinical red flags and imaging red flags (iRF) for early detection and treatment of CA. Unluckily data suggests that these patients visit 4-5 physicians before being diagnosed with CA; this is mainly due to perception of rarity, overlapping symptomatology with other common cardiac conditions (hypertension, chronic renal failure, aortic stenosis, and hypertrophic cardiomyopathy), and inability of identification of clinical and iRF of CA by the practicing physicians in the routine outpatient department (OPD) working. Recently published multiregional expert consensus on multimodality correlative cardiac imaging by international societies has emphasized on specific clinical and imaging red flags (iRF) using ECG, echocardiogram, 99mTc-based scintigraphy, and cardiac MR for robust diagnosis of CA. However, reading all these tedious guidelines and retaining their diagnostic practice points (DPPs) appears difficult in daily practice for practicing physicians and residents. Therefore, the current draft has condensed and highlighted the DPPs of recent 5 years of published data in the form of concise, printable tables and flow charts, enabling a physician in the OPD to flick through, teach, and direct the suspected patients for prompt and timely diagnostic testing to rule out CA.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Fatima Abdullahi, Khalid Makhdomi, Jasmit Shah, Samuel Gitau
{"title":"Prolonged fasting for optimizing myocardial fluorodeoxyglucose suppression.","authors":"Fatima Abdullahi, Khalid Makhdomi, Jasmit Shah, Samuel Gitau","doi":"10.1097/MNM.0000000000002061","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002061","url":null,"abstract":"<p><strong>Background: </strong>PET with 18F-fluorodeoxyglucose (18F-FDG) is widely used to evaluate inflammatory cardiac disorders such as sarcoidosis and myocarditis. However, physiologic myocardial uptake can obscure pathological uptake and must be suppressed.</p><p><strong>Objective: </strong>To determine the effectiveness of fasting alone in suppressing physiological myocardial uptake and to establish a practical imaging protocol.</p><p><strong>Methods: </strong>We retrospectively reviewed patients who underwent whole-body 18F-FDG PET/CT for oncologic indications between January 2019 and December 2020. Patients were categorized by fasting duration: Group A (<12 h), Group B (12-17 h), and Group C (≥18 h). Two independent readers qualitatively graded myocardial FDG uptake, with adequate suppression defined as grade 0 (no uptake) or grade 1 (uptake ≤ liver background). Uptake above liver background (grade 2) was considered inadequate. Interreader agreement was assessed using Cohen's Kappa.</p><p><strong>Results: </strong>A total of 450 patients were included (150 per group). Adequate myocardial suppression was achieved in 77.3, 66, and 60% of patients in Groups C, B, and A, respectively (P = 0.005). Suppression was not associated with blood glucose, age, or diabetes. However, significant associations were observed with gender (P = 0.024) and BMI (P = 0.006). Interreader agreement was almost perfect (Cohen's Kappa 0.909; 95% CI: 0.868-0.950).</p><p><strong>Conclusion: </strong>Fasting for ≥18 h is more effective than shorter durations in suppressing physiologic myocardial FDG uptake, enabling evaluation of myocardial inflammation. This simple and feasible protocol is particularly valuable in resource-limited settings. Visual grading demonstrated excellent reproducibility, supporting its role in clinical practice.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinical phenotypes among patients that underwent cardiac resynchronization therapy using unsupervised learning integrating gated SPECT.","authors":"Giovane Leal de Azevedo Junior, Noah Painter, Zhuo He, Kristoffer Larsen, Qiuying Sha, Xinwei Zhang, Jiangang Zou, Guang-Uei Hung, Amalia Peix, Claudio Tinoco Mesquita, Weihua Zhou","doi":"10.1097/MNM.0000000000002055","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002055","url":null,"abstract":"<p><strong>Background: </strong>Cardiac resynchronization therapy (CRT) is an effective treatment for heart failure when left ventricular mechanical dyssynchrony (LVdys) is present, yet approximately 30-40% of patients do not respond to therapy. The purpose of this study is to use unsupervised learning to identify phenotypes of patients with a better response rate.</p><p><strong>Methods: </strong>Unsupervised learning integrating gated single-photon emission computed tomography (SPECT) was used to identify clinical phenotypes among patients undergoing CRT. We utilized hierarchical clustering analysis to group 217 patients based on 49 pretreatment variables, including demographic, clinical, and phase analysis of gated SPECT data. Fibrosis was measured by the percentage of pixels with less than 50% of maximum relative counts. LVdys was evaluated by phase SD >43° and phase bandwidth >135°.</p><p><strong>Results: </strong>We identified three phenotypes of patients: two with similar response rates (86.2 and 87.0%) but with different characteristics, one presenting borderline LVdys, low fibrosis and nondilated heart and the other high LVdys, moderate fibrosis and a dilated heart; the third phenotype represents patients with moderate LVdys, substantial amounts of cardiac fibrosis and a dilated heart that do not have a good response to CRT (55.9%).</p><p><strong>Conclusion: </strong>Our results suggest that evaluating cardiac dyssynchrony, fibrosis, and remodeling through phase analysis of gated SPECT is relevant in characterizing the phenotype of good responders. Patients with substantial amounts of cardiac fibrosis have less benefit from CRT. This work suggests that CRT recommendations based on customized selection criteria associated with gated SPECT can lead to higher response rates.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Olof Jonmarker, Michael Sunderland, Lotte Steffens, Carl Samuelsson, Darin O'Keeffe, Janvi Puri, Stefan Erik Olof Gabrielson
{"title":"Retrospective analysis of [99mTc]Tc-HYNIC-PSMA single photon emission computed tomography CT in patients with prostate cancer.","authors":"Olof Jonmarker, Michael Sunderland, Lotte Steffens, Carl Samuelsson, Darin O'Keeffe, Janvi Puri, Stefan Erik Olof Gabrielson","doi":"10.1097/MNM.0000000000002060","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002060","url":null,"abstract":"<p><strong>Objective: </strong>Prostate cancer is one of the most common malignancies in men. While multiparametric MRI is the gold standard for local staging of prostate cancer, accessibility may be limited. The same is true for Prostate Specific Membrane Antigen (PSMA) PET/computed tomography (CT). This study evaluates the diagnostic performance of [99mTc]Tc-PSMA single photon emission computed tomography (SPECT) as an alternative molecular imaging modality.</p><p><strong>Methods: </strong>This retrospective study of 82 patients with newly diagnosed prostate cancer compares the performance of [99mTc]Tc-PSMA SPECT/CT with multiple readers, with MRI, and with respect to histopathological correlation from biopsies. SPECT/CT findings were evaluated both locally, using a standardised 12-segment prostate model, and with respect to metastases. Agreement between modalities and readers was measured using intraclass correlation and Cohen's kappa.</p><p><strong>Results: </strong>PSMA SPECT/CT identified clinically relevant prostate lesions with the best interreader agreement for bone metastases and laterality, and poorest agreement for extraprostatic extension and seminal vesicle invasion. Sector-based comparison showed PSMA SPECT/CT to have comparable detection rates to MRI. Higher SPECT standardised uptake values (SUV) were associated with stronger concordance with biopsy results, higher than both the low SPECT SUV group and clinical MRI readings.</p><p><strong>Conclusion: </strong>[99mTc]Tc-PSMA SPECT/CT demonstrates promise as an alternative to MRI in the primary staging of prostate cancer, particularly in high SPECT SUV settings. While MRI remains more sensitive for local extension, PSMA SPECT may offer complementary value in comprehensive staging, especially in a resource-limited setting.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cigdem Soydal, Ecenur Dursun Avci, Irem Mesci, Emre Can Celebioglu, Digdem Kuru Oz, Nuriye Ozlem Kucuk
{"title":"Dose-response relationship in patients who received transarterial radioembolization with Y-90 resin microspheres for hepatocellular carcinoma.","authors":"Cigdem Soydal, Ecenur Dursun Avci, Irem Mesci, Emre Can Celebioglu, Digdem Kuru Oz, Nuriye Ozlem Kucuk","doi":"10.1097/MNM.0000000000002058","DOIUrl":"https://doi.org/10.1097/MNM.0000000000002058","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to analyze the dose-response relationship in hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with Y-90 resin microspheres.</p><p><strong>Methods: </strong>Patients who received TARE with Y-90 resin microspheres using multicompartment dosimetry between February 2020 and December 2024 were included in the analysis. A total of 46 lesions from 21 patients were included in the dose-response analysis. Multicompartment dosimetry was performed for all lesions in the perfused area. Additionally, the mean tumor absorbed dose (TAD), whole-liver absorbed dose, and perfused-liver absorbed dose were calculated.</p><p><strong>Results: </strong>All the patients received Y-90 resin microspheres with a lobar or segmental approach. Median tumor volume was calculated as 9.4 cm³ (min-max: 1-1674). During the third-month evaluation, 21 lesions were responders. In the receiver operating characteristic analysis, a 104 Gy cutoff for mean TAD [AUC: 0.693, 95% confidence interval (CI): 0.532-0.853, P = 0.018] was calculated for response, with 76% sensitivity and 64% specificity. For the prediction of complete response, we found a 159 Gy cutoff for mean TAD (AUC: 0.776, 95% CI: 0.598-0.953, P = 0.002), with 70% sensitivity and 79% specificity.</p><p><strong>Conclusion: </strong>We demonstrated a strong relationship between absorbed tumor dose and treatment response in HCC patients who received TARE with Y-90 resin microspheres. Delivery of approximately 100 Gy mean absorbed dose to the tumor is needed to achieve a response. Increasing the TAD to ~160 Gy would be expected to result in a complete response.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145207313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Radionuclide radiologists: an untapped resource to bolster the nuclear medicine workforce.","authors":"Joshua G Vaughan-Ward","doi":"10.1097/MNM.0000000000002034","DOIUrl":"10.1097/MNM.0000000000002034","url":null,"abstract":"","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":"46 10","pages":"1018"},"PeriodicalIF":1.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}